Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1955 3
1956 2
1958 2
1959 1
1960 2
1961 3
1962 1
1963 4
1964 3
1967 1
1968 4
1969 6
1970 4
1971 2
1972 1
1973 1
1975 4
1976 4
1977 2
1978 5
1979 2
1980 7
1981 5
1982 7
1983 7
1984 11
1985 11
1986 9
1987 12
1988 7
1989 9
1990 16
1991 8
1992 11
1993 9
1994 14
1995 7
1996 10
1997 12
1998 20
1999 33
2000 30
2001 44
2002 23
2003 29
2004 31
2005 35
2006 44
2007 32
2008 25
2009 27
2010 36
2011 37
2012 28
2013 30
2014 41
2015 50
2016 47
2017 47
2018 54
2019 55
2020 62
2021 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,015 results
Results by year
Filters applied: . Clear all
Page 1
Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
Tamiya M, Tamiya A, Suzuki H, Moriizumi K, Nakahama K, Taniguchi Y, Kunimasa K, Kimura M, Inoue T, Kuhara H, Nishino K, Hirashima T, Atagi S, Imamura F, Kumagai T. Tamiya M, et al. Among authors: kumagai t. Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544. Anticancer Res. 2019. PMID: 31262922
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Nakagawa K, et al. Among authors: kumagai t. Lung Cancer. 2020 Jan;139:195-199. doi: 10.1016/j.lungcan.2019.11.025. Epub 2019 Nov 28. Lung Cancer. 2020. PMID: 31812890
Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis.
Kato M, Ikeda K, Kageyama T, Kasuya T, Kumagai T, Furuya H, Furuta S, Tamachi T, Suto A, Suzuki K, Nakajima H. Kato M, et al. Among authors: kumagai t. J Clin Rheumatol. 2019 Jan 4. doi: 10.1097/RHU.0000000000000984. Online ahead of print. J Clin Rheumatol. 2019. PMID: 30614890 No abstract available.
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
Morita R, Okishio K, Shimizu J, Saito H, Sakai H, Kim YH, Hataji O, Yomota M, Nishio M, Aoe K, Kanai O, Kumagai T, Kibata K, Tsukamoto H, Oizumi S, Fujimoto D, Tanaka H, Mizuno K, Masuda T, Kozuki T, Haku T, Suzuki H, Okamoto I, Hoshiyama H, Ueda J, Ohe Y. Morita R, et al. Among authors: kumagai t. Lung Cancer. 2020 Feb;140:8-18. doi: 10.1016/j.lungcan.2019.11.014. Epub 2019 Nov 20. Lung Cancer. 2020. PMID: 31838169 Free article.
Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly.
Yoneda Y, Haginoya K, Kato M, Osaka H, Yokochi K, Arai H, Kakita A, Yamamoto T, Otsuki Y, Shimizu S, Wada T, Koyama N, Mino Y, Kondo N, Takahashi S, Hirabayashi S, Takanashi J, Okumura A, Kumagai T, Hirai S, Nabetani M, Saitoh S, Hattori A, Yamasaki M, Kumakura A, Sugo Y, Nishiyama K, Miyatake S, Tsurusaki Y, Doi H, Miyake N, Matsumoto N, Saitsu H. Yoneda Y, et al. Among authors: kumagai t. Ann Neurol. 2013 Jan;73(1):48-57. doi: 10.1002/ana.23736. Epub 2012 Dec 7. Ann Neurol. 2013. PMID: 23225343
Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. Arai S, et al. Among authors: kumagai t. J Thorac Oncol. 2020 May;15(5):752-765. doi: 10.1016/j.jtho.2020.01.001. Epub 2020 Jan 21. J Thorac Oncol. 2020. PMID: 31972351 Free article.
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N. Nishio M, et al. Among authors: kumagai t. J Thorac Oncol. 2020 Nov 25:S1556-0864(20)31026-1. doi: 10.1016/j.jtho.2020.11.004. Online ahead of print. J Thorac Oncol. 2020. PMID: 33248320 Free article.
Prenatal clinical manifestations in individuals with COL4A1/2 variants.
Itai T, Miyatake S, Taguri M, Nozaki F, Ohta M, Osaka H, Morimoto M, Tandou T, Nohara F, Takami Y, Yoshioka F, Shimokawa S, Okuno-Yuguchi J, Motobayashi M, Takei Y, Fukuyama T, Kumada S, Miyata Y, Ogawa C, Maki Y, Togashi N, Ishikura T, Kinoshita M, Mitani Y, Kanemura Y, Omi T, Ando N, Hattori A, Saitoh S, Kitai Y, Hirai S, Arai H, Ishida F, Taniguchi H, Kitabatake Y, Ozono K, Nabatame S, Smigiel R, Kato M, Tanda K, Saito Y, Ishiyama A, Noguchi Y, Miura M, Nakano T, Hirano K, Honda R, Kuki I, Takanashi JI, Takeuchi A, Fukasawa T, Seiwa C, Harada A, Yachi Y, Higashiyama H, Terashima H, Kumagai T, Hada S, Abe Y, Miyagi E, Uchiyama Y, Fujita A, Imagawa E, Azuma Y, Hamanaka K, Koshimizu E, Mitsuhashi S, Mizuguchi T, Takata A, Miyake N, Tsurusaki Y, Doi H, Nakashima M, Saitsu H, Matsumoto N. Itai T, et al. Among authors: kumagai t. J Med Genet. 2020 Jul 30:jmedgenet-2020-106896. doi: 10.1136/jmedgenet-2020-106896. Online ahead of print. J Med Genet. 2020. PMID: 32732225
1,015 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page